3rd Annual Conference on Gynecologic Oncology & Preventive Oncology July 20-21, 2017 Chicago, Illinois, USA

Michael Retsky (Ph.D in physics from University of Chicago) made a career change from physics to cancer research. He is Editor-in-Chief of Journal of Bioavailability and Bioequivalence, on staff at Harvard School of Public Health, honorary faculty at University College London, and Prof Adj at UANL, Monterrey, Mexico. He was on Judah Folkman’s staff at Harvard Medical School for 12 years. He is on the board of directors of the Colon Cancer Alliance and has published more than 60 papers in physics and cancer. He has a patent pending for treatment of early stage cancer

cancer research, charged particle optics, early detection of cancer and delayed detection of cancer

Dr. Nezami is a board certified physician graduated from USC and UCSF residencies. He has functioned as a faculty teacher during his training as well as invited presenter at society of teachers in Family medicine. He has been in practice for 18 years and currently is the president of Pacific Medical Center of Hope in California. He is promoting research in conventional oncology, in cutting edge. Dr Nezami serves as national and international speaker in oncology and epigenetic science. He has been involved in many research projects and publications, presentations ( including integrative medicine, Epigenetic therapies 2013 Barcelona Conference on Epigenetics and Cancer, Society of integrative oncology, American Association for Cancer Research ( AACR), Molecular Medicine Triconference, World Molecular Imaging, and World Pharmaceutical Congress, NCI-AACR, .... Author, Integrative Medicine, A Clinician Journal, as well as author and coauthor in oncology literature. (Surveillance in lymphoma, published 2006, Cancer Science 2015, JCT 2015, 2016, Precision medicine,.....). He is a co author of Weil’s " Textbook for integrative oncology." (2014) Dr. Nezami is an inventor and innovator and has designed new method of treating advanced cancer, called Modified Multi Molecular Targeted Epigenetic Therapy (MTET). With this method, during the last 7 years, he has successfully treated many patients, mostly with advanced stage four cancer who had failed all other conventional methods. Several cancer institutions, including MD Anderson cancer center and private oncology centers have already started investigating his method in either preclinical or clinical settings, showing extra ordinary results. ( His case studies have been approved by the NCI oncology and research consultants to be an effective method of treating cancer.) Dr. Nezami has served as principal investigator by NIH, National Institute of Health; for TACT trial and has been involved both in research and publications, as coauthor, with National cancer institute (NCI) in the best case series of complimentary and alternative cancer therapies in the country. He also serves as speaker and medical consultant for Caris Life Sciences ( Caris Oncology Laboratory) and provides scientific expert review at Journal of Cancer Therapy ( JCT) and British Journal of Medicine and Medical Research, ( BJM) as well as serving as peer review expert in multidisciplinary scientific journals, ( ex. "Archivum Immunologiae Et Therapiae Experimentalis"), in oncology. His main area of interest are integrative oncology and epigenetics. He currently teaches and consults other physicians and oncologists and is extensively involved in research and pursuing clinical trials in this field.

Sequential targeted therapy in Cancer Applications and methods of treating actionable targets in multiphase approach

Mahir Khalil Ibrahim Jallo, an Associate Professor of Medicine & Senior Consultant Endocrinologist. He granted his MB, ChB from Mosul University College of Medicine in IRAQ 1981, his postgraduate Arab Board Certification in Internal Medicine CABM in1992, Fellowship of The American College of Endocrinology FACE in 2015 and certified with Diploma in Dyslipidemia from Boston University School of Medicine, USA in 2014. He is the Coordinator for MBBS Endocrinology Module in GMU, Editorial Board for many international journals and active Principle Investigator in many national & international clinical studies, Member of AACE, EASD, ESE, ISPAD and many professional societies. To his credit many awards of honor & publications in medical periodicals and conference abstracts.

Internal Medicine, Cancer Prevention, Endocrinology,